Skip to main content

Health: Drugs

Volume 706: debated on Wednesday 14 January 2009


Asked by

To ask Her Majesty's Government what discussions they will have with relevant agencies in the National Health Service about the number of new drugs for gram-negative bacterial infection. [HL314]

As part of our commitment to tackle healthcare associated infections (HCAIs), the department has regular discussions with relevant bodies about the control of gram-negative and other infections. These bodies include the Health Protection Agency, the Advisory Committee on Antimicrobial Resistance and Healthcare Associated Infection and professional societies.

Two licences have been granted by the European Medicines Agency within the past three years for new antibacterial drugs active against gram-negative bacteria. They relate to tigecycline (brand name Tygacil), authorised on 24 April 2006; and doripenem (brand name Doribax), authorised on 25 July 2008.

Our strategy on HCAIs includes a number of different initiatives and approaches to reduce infection rates. One of these is the Healthcare Associated Infection Technology Innovation Programme, launched in January 2008, which is designed to accelerate the development and adoption of new and novel technologies through partnership with the National Health Service, industry and academia.